1. Home
  2. FCAP vs SCLX Comparison

FCAP vs SCLX Comparison

Compare FCAP & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Capital Inc.

FCAP

First Capital Inc.

N/A

Current Price

$48.15

Market Cap

125.9M

Sector

Finance

ML Signal

N/A

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$19.93

Market Cap

139.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCAP
SCLX
Founded
1891
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
125.9M
139.3M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
FCAP
SCLX
Price
$48.15
$19.93
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
4.0K
122.8K
Earning Date
01-23-2026
11-14-2025
Dividend Yield
2.44%
N/A
EPS Growth
25.19
N/A
EPS
4.41
N/A
Revenue
$47,323,000.00
$40,360,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$749.70
P/E Ratio
$11.52
N/A
Revenue Growth
15.22
N/A
52 Week Low
$28.50
$3.60
52 Week High
$53.85
$34.27

Technical Indicators

Market Signals
Indicator
FCAP
SCLX
Relative Strength Index (RSI) 69.75 51.13
Support Level $47.48 $18.34
Resistance Level $50.95 $20.62
Average True Range (ATR) 0.99 2.22
MACD 0.37 -0.02
Stochastic Oscillator 97.55 32.91

Price Performance

Historical Comparison
FCAP
SCLX

About FCAP First Capital Inc.

First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: